Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+

Abroad (travel likely)RecruitingPHASE2

Conditions

Diffuse Large B-cell Lymphoma · DLBCL - Diffuse Large B Cell Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Virginia Commonwealth University, Richmond, Virginia, United States
Contact: Study coordinator (Massey Heme Malig Team) · MasseyHemMlg@vcu.edu · 804-628-6430
Contact: Principal Investigator (Bruce Hough, MD)

Study leads

Bruce Hough, MD
Principal Investigator
Virginia Commonwealth University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients With DLBCL Intolerant to Chemotherapy

DLBCL · Diffuse Large B-Cell Lymphoma

Abroad (travel likely)RecruitingPHASE2

Ningbo, China

SynKIR-310 for Relapsed/Refractory B-NHL

B Cell Lymphoma · NHL, Adult · Mantle Cell Lymphoma

Abroad (travel likely)RecruitingPHASE1

Denver, United States · Atlanta, United States

Real-World Study of DLBCL With Different Genetic Subtypes

DLBCL - Diffuse Large B Cell Lymphoma · Lymphoma

Abroad (travel likely)Recruiting

Shanghai, China

Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype

Richter Syndrome · Diffuse Large B-Cell Lymphoma · Chronic Lymphocytic Leukemia

Abroad (travel likely)RecruitingPHASE2

Buffalo, United States